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Abstract
The heavy metals (HMs) lead and cadmium are persistent environmental pollutants capable of
inducing ill-health in exposed individuals. One of the primary sites of accumulation and poten-
tial damage from HMs is bone, and we therefore examined the acute effects of lead and cad-
mium on human bone osteoblasts in vitro over a concentration range of 0.1 μM to 1mM, and
for 3, 6, 12, 24, and 48 hour exposures. Incubation of osteoblasts with either lead or cadmium
reduced cell viability in a concentrations and exposure durations dependent manner, as mea-
sured using MTT and LDH assays. Cytotoxicity was significant from 0.1 μM concentrations
after 48 hour exposures. Both HMs damaged cellular bioenergetics with reductions of ATP pro-
duction, mitochondrial complex activities, and aerobic respiration. There was a concomitant
elevation of reactive oxygen species, with induction of redox stress measured as increased
lipid peroxidation, and depleted cellular redox defense systems via reduced superoxide dismut-
ase and catalase activity and cellular glutathione levels. Both HMs induced nuclear activation
of Nrf2, presumably to increase transcription of antioxidant responsive genes to combat oxida-
tive stress. Incubation of osteoblasts with HMs also compromised the secretion of procollagen
type 1, osteocalcin, and alkaline phosphatase. Pre-incubation of osteoblasts with reduced glu-
tathione prior to challenge with HMs lessened the cytotoxicity of the HMs, indicative that antiox-
idants may be a beneficial treatment adjunct in cases of acute lead or cadmium poisoning.
Introduction
Heavy metals (HMs) such as lead, cadmium, mercury, and arsenic are worldwide environmen-
tal pollutants with multiple adverse health effects [1]. Humans may experience occupational or
environmental exposure to HMs usually via inhalation, dermal, or ingestion routes, primarily
via contaminated air, soil, water, or foodstuffs, respectively [2]. For some HMs, bone can be a
primary target for HM accumulations and toxic damage. For example, bones may sequester
and store lead, which can be subsequently remobilized during childhood or pregnancy, with
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neurotoxic or teratogenic properties, respectively [3–5]. Although higher bone mineral density
(BMD) has been attributed to higher lead exposure in children [6], reduced BMD correlated
with lead exposure in certain adult cohorts [7].
Kidney damage typifies environmental toxicity from cadmium exposures. However, cad-
mium also damages other tissues including lung, liver, and testis as well as exerting toxic effects
upon bones. Bone softening (osteomalacia), reduced bone density (osteoporosis), increased
bone fracture risk, and the development of Itai-Itai disease (cadmium-induced renal tubular
osteomalacia) are clinical outcomes for humans that have experienced environmental expo-
sure to cadmium [8–13].
The harmful effects of HMs may arise through organ toxicity such as cadmium-induced
renal damage, or through secondary effects on metabolism, influencing vitamin D activation
and calcium hemostasis [14–17]. Additionally, HMs may exert direct effects on bone cells,
influencing bone formation and/or resorption.
Bone is essential for locomotion and skeletal function, with a principal function of provi-
sion of resistance to mechanical forces. The composition of bone is approximately 60%
mineral crystals, 30% organic matrix, and 10% cells. There are four cell types: osteoblasts,
osteoclasts, osteocytes, and bone lining cells [18]. Bone in not inert but a dynamic tissue that
undergoes a continuous process of renewal through bone remodeling, via a balance between
matrix synthesis by osteoblasts (of mesenchymal origin) and bone resorption by osteoclasts (of
hematopoietic origin) [19,20]. An imbalance between matrix formation and resorption, results
in net bone loss, as in cases of osteoporosis [21,22].
Osteoblasts are differentiated, cuboidal cells that line the bone surface and are responsible
for bone matrix protein production; this includes the secretion of collagen (mainly type I) and
non-collagenous proteins including osteocalcin, osteopontin, bone sialoprotein II, and alkaline
phosphatase (ALP), crucial for bone mineralization [18].
To date, there is no level of exposure to lead that is without risk, indeed exposure to lead
has been estimated to account for over half a million deaths in 2016 [23]. Lead accumulation
in tissues promotes oxidative DNA damage, and causes anemia, in part through inhibition of
the activity of δ-aminolevulinic acid dehydratase, an enzyme involved in the biosynthesis of
heme [17, 24]. Cadmium exposure is also a major health concern, with cadmium classified as a
human carcinogen [25,26]. In addition to their genotoxic effects, acute exposure to lead or cad-
mium triggers tissue damage and cell death via oxidative stress, depletion of protein thiols,
mitochondrial dysfunction, and apoptosis [16,17,27–33]. Both heavy metals reduce activities
of antioxidant defense enzymes and cellular glutathione levels, and promote lipid peroxidation
in a number of target tissues [16,17,27–33].
Although lead and cadmium represent the two most abundant toxic metals and for which
tissue toxicity has been extensively studied, their acute toxicity to bone cells has not been
completely delineated. Furthermore, there is a need to establish the threshold lead or cadmium
exposure that triggers osteoblast damage, and delineate the mechanisms of toxicity. To address
this we have considered the cytotoxic effects of lead and cadmium after direct application to
human osteoblasts in vitro. Additionally, we have considered the effects of both HMs upon cel-
lular bioenergetics, the generation of redox stress, and whether HM administration influences
osteoblast secretory functions.
Material and methods
2.1 Chemicals and reagents
All chemicals, including the heavy metal solutions lead nitrate and cadmium dichloride, were
purchased from Sigma (St. Louis, MO, USA), unless mentioned otherwise. For studies of
Osteoblasts and lead and cadmium
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oxygen consumption rates, Hank’s solution was prepared as described by Daunt et al. [34] and
contained 5.6 mM KCl, 138 mM NaCl, 4.2 mM NaHCO3, 1.2 mM NaH2PO4, 2.6 mM CaCl2,
1.2 mM MgCl2, 10 mM HEPES (pH 7.4 with NaOH), and 0.1% (w/v) bovine serum albumin
(BSA).
2.2 Cell culture
Osteoblasts were purchased from PromoCell (Heidelberg, Germany) and used at passages 4–5
for all studies. Cells were grown in Human Osteoblast Growth Medium and incubated at
37˚C, 5% CO2 in a humidified incubator.
2.3 Cytotoxicity assessment using MTT and LDH assays
Osteoblasts were seeded at a density of 2 x 104 cells/well, and grown to 90% confluence. Cells
were then treated with Pb or Cd at concentrations of (0.1, 1, 10, 100, and 1000 μM) for 3, 6, 12,
24, or 48 hrs. The production of reduced MTT substrate as a measure of cell metabolic activ-
ity/viability was quantified spectrophotometrically at 590 nm according to the manufacturer’s
protocol. All assay points were performed in triplicate. MTT absorbance values are expressed
as percentages of control wells (defined as 100%).
For MTT assays performed in the presence of reduced glutathione, osteoblasts were
prepared as before, but prior to treatment with HMs, cells were pre-incubated with 10 μM
reduced GSH for 24 hours.
A commercially available kit was used to measure LDH levels, with methods followed
according to the manufacturer’s protocol (Clontech, Mountain View, California, USA). Cells
were seeded as for the MTT assay, and likewise incubated at the concentrations and for the
durations detailed for the MTT assay. The release of LDH was measured spectrophotometri-
cally at 490 nm using a plate reader ‘TopCount’ (Perkin Elmer, Ueberlingen, Germany). Posi-
tive control wells containing 2% Triton X-100 were used to provide a reference for total cell
lysis. Cell cytotoxicity and the associated release of LDH was calculated as a percentage of the
positive control.
2.4 Measurements of osteoblast proliferation
Osteoblast were seeded in 96 well plates at 2 x 104 cells/well and then grown overnight. Cells
were then treated with Pb (55 μM) or Cd (30 μM) for 12, 24, 48, 72, or 96 hrs. This concentra-
tion of HM reflects the estimated IC50 concentrations as determined using the MTT assay.
5-bromo-2’-deoxyuridine (BrdU) proliferation assays were performed according to the manu-
facturer’s guide (Millipore, Massachusetts, USA). Briefly, BrdU cell proliferation reagent was
added at least 2 hr before the end of the incubation period with the HMs. After this HM incu-
bation period, media was aspirated and 200 μl of fixing solution added per well, and samples
incubated at room temperature for 30 minutes before aspiration. Well washing with a wash
buffer was performed prior to the addition of 100 μL/well of diluted anti-BrdU monoclonal
antibody, and incubation for 1 hour at room temperature. After well washing, goat anti-mouse
IgG 100 μL/well was added, and the plate incubated for 30 minutes at room temperature. After
further well washing, the plate was air dried. One hundred μL of peroxidase substrate was
added to each well and the plate incubated in the dark for 30 minutes, and then the reaction
stopped by pipetting 100 μL of acid stop solution to each well. The absorbance at 450 nm was
measured using a microplate reader. All assay points were performed in triplicate, with control
well values subtracted from test samples.
Osteoblasts and lead and cadmium
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2.5 Measurements of intracellular ATP levels
Osteoblasts were seeded at 2 x 104 cells/well and grown to 90% confluence, before treatment
with Pb (55 μM) or Cd (30 μM) for 24 hrs. Levels of intracellular ATP were then measured
according to a kit protocol (Abcam, Cambridge, UK). ATP levels, measured as luminescence,
were detected by single photon counting with values quantified relative to control well
readings.
2.6 Measurements of mitochondrial membrane potential
Osteoblasts were seeded in 24-well plates at 3 x 104 cells/well. At confluence, cells were treated
with Pb (55 μM) or Cd (30 μM). After 24 hrs, media were removed and cells incubated with a
staining solution of mitotracker green (50 nM) at 37 ˚C. After 30 minutes, stained cells were
retained in fresh phosphate buffered saline. Fluorescence was measured using a fluorescence
microplate reader ‘TopCount’ (Perkin Elmer, Ueberlingen, Germany), using excitation and
emission filters of 490 nm and 516 nm, respectively. Carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP) was used as a positive control to trigger membrane uncoupling.
2.7 Measurements of mitochondrial complex activities
Osteoblasts were seeded at 4 x 104 cells/well in six well plates, and incubated for 24 hrs with
either Pb (55 μM) or Cd (30 μM) as determined using the MTT assay. A mitochondrial
enriched fraction for complex I assay and cell lysate for complex III assay were prepared
according to Spinazzi et al. [35]. Complex I activity was measured following the protocol of
Janssen et al [36]. Complex III activity was assayed according to Spinazzi et al. [35]. Dichlor-
oindophenol (DCIP) was used as the terminal electron acceptor.
2.8 Measurements of lactate production
Cells were seeded in 24-well plates at 5 x 104 cells/well, and treated with Pb (55 μM) or Cd
(30 μM) for 24 hrs. Cells were trypsinized, and then briefly spun at 1000 x g for 5 minutes. Pel-
leted cells were counted whereas the supernatant media was retained and assayed for lactate
levels using a lactate assay kit (Biovision, Mountain View, California, USA) according to the
manufacturer’s instructions. Lactate production was normalized to cell number and expressed
as a percentage of control lactate production.
2.9 Measurements of oxygen consumption rate
The oxygen consumption rate (OCR) of osteoblast suspensions of known cell density was mea-
sured polarographically using Clark oxygen electrodes (Rank Brothers, Bottisham, UK), simi-
lar to a previous publication [37]. Cells were incubated with Pb (55 μM) or Cd (30 μM) for 24
hours. Cells were harvested by trypsinization, centrifuged and re-suspended in Hank’s solution
and counted using a haemocytometer. The OCR was then assessed under basal conditions for
10 minutes before 2 μl of 6 mM azide was added to each chamber. The OCR was measured as
the change in PO2 level over a 300-sec period with the azide slope measured 60 seconds after
its addition. The majority of PO2 changes were linear under these conditions.
2.10 Measurements of reactive oxygen species
The relative levels of ROS generated in response to treatment with Pb or Cd were calculated
based upon a 2,7-dichlorodihydrofluorescein diacetate (DCFDA) assay as described in a previ-
ous publication [38]. Osteoblast incubation with Antimycin A (10 mM for 30 min) was used as
a positive control, with non-stained cells used for negative control values.
Osteoblasts and lead and cadmium
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2.11 Measurements of catalase activity
Catalase (CAT) activity was assayed colorimetrically at 620 nm and expressed as μmoles H2O2
consumed/min/mg of protein using the method described by Singh et al. [39]. Assays were
performed 24 hrs post-exposure to HMs. The reaction mixture (1.5 mL) contained 1.0 mL of
0.01M pH 7 phosphate buffer, 0.1 mL of tissue homogenate and 0.4 mL of 2M H2O2. The reac-
tion was stopped by the addition of 2 mL of dichromate-acetic acid reagent.
2.12 Measurements of superoxide dismutase activity
Superoxide dismutase (SOD) activity measurements were based on SOD-mediated inhibition
of the reduction of nitroblue tetrazolium to blue formazan by superoxide anions as described
by Beauchamp and Fridovich [40]. Units of SOD activity were expressed in terms of mg of
total protein.
2.13 Measurements of reduced glutathione
Reduced glutathione (GSH) was determined based upon the original method of Ellman as
described by Ullah et al. [41]. Absorbance values were measured spectrophotometrically at 412
nm using a plate reader ‘TopCount’ (Perkin Elmer, Ueberlingen, Germany). The activity of
GSH was expressed as nM reduced GSH/g tissue.
2.14 Measurements of lipid peroxidation
Thiobarbituric acid reactive substances (TBARS) were quantified as markers of lipid peroxida-
tion [42]. Osteoblasts were treated with Pb (55 μM) or Cd (30 μM) (IC50 concentrations
according to the MTT assay), and also at 10 μM for 24 hrs. Media was removed, cells were har-
vested, and then a TBARS assay performed according to Alam et al. [43].
2.15 Measurements of Nrf2 activation
Activation of Nrf2 was studied using a Nrf2 Transcription Factor Assay Kit (Abcam, Cam-
bridge, UK). Osteoblasts were seeded in 75 cm2 flasks and grown to 90% confluence, before
treatment with Pb (55 μM) or Cd (30 μM) for 24 hours. Nuclear extracts were prepared
according to the assay kit protocol, protein concentrations determined using a Bradford assay,
and then samples stored at -80 ˚C until required for assay. Assays for Nrf2 activation followed
the manufacturer’s guidelines. Briefly, 40μl of binding buffer was added to each well of a 96
well assay plate, and then 15 μg of nuclear extract added in 10μl of lysis buffer. The plate was
sealed and incubated at room temperature on a rocking platform for 1 hour, and then each
well washed three times with wash buffer before addition of anti-Nrf2 primary antibody
(100μl/well) and the plate then incubated for 60 minutes. Wells were washed before secondary
antibody applied at room temperature for 1 hour. Finally, the developing solution was added
(100μl/well) and plate incubated in the dark for 10 minutes before the addition of stopping
solution. Well absorbance was read at OD 450nm (Perkin Elmer, Ueberlingen, Germany),
with blank readings subtracted from final absorbance values. All assay points were performed
in triplicate.
2.16 Effect of HMs on procollagen secretion
Osteoblasts were seeded at 4 x 103 cells/well in 96-well plates and grown to 80–90% confluency.
Cells were then treated with Pb (55 μM) or Cd (30 μM) for 24 hrs. Media was collected, soni-
cated, and procollagen type I C-Peptide (PIP) quantified using an ELISA kit (Takara Shuzou,
Japan), with PIP concentrations interpolated from a standard curve. Cells were homogenized
Osteoblasts and lead and cadmium
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in phosphate buffered saline containing 0.5% Triton X-100, 1 mM ethylenediaminetetraacetic
acid, and 1 mM phenylmethylsulfonyl fluoride, with procollagen content determined as for
media and normalized to cell number.
2.17 Effect of HMs on osteocalcin secretion
Osteoblasts were seeded at 4 x 103 cells/well in 96-well plates and grown to 80–90% confluency.
Cells were then treated with Pb (55 μM) or Cd (30 μM) for 3, 6, 12, 24 or 48 hrs. Media were
collected and the levels of osteocalcin determined using a sandwich enzyme-linked immuno-
sorbent assay (ELISA) kit (Takara Shuzou, Japan), with osteocalcin concentrations interpo-
lated from a standard curve.
2.18. Effect of HMs on alkaline phosphatase secretion
Osteoblasts were seeded at 4 x 106 cells/well in 24-well plates and grown to 80–90% confluency.
Cells were treated with Pb (55 μM) or Cd (30 μM) for 3, 6, 12, 24 and 48 hrs. Media was col-
lected, and alkaline phosphatase (ALP) activity evaluated using a commercially available kit
following the manufacturer’s protocol (Abcam, Cambridge, UK). A p-nitrophenyl phosphatase
assay was used to measure ALP activity within media, and quantified spectrophotometry at
405 nm using a TopCount plate reader (Perkin Elmer, Ueberlingen, Germany).
2.19 Statistical analysis
All statistical analyses were performed using PRISM 5 (GraphPad Software Inc., San Diego,
California, USA). One way analysis of variance (ANOVA) test with Dunn’s multiple compari-
sons post-test or unpaired student t-test were used for comparisons of the different groups
data. Statistical significance was defined as p< 0.05.
Results
3.1 Pb and Cd are cytotoxic to human osteoblasts
Human osteoblasts were incubated with the HMs, lead (Pb) or cadmium (Cd) over a broad
concentration range of 0.1 μM to 1 mM, and the level of cytotoxicity quantified after 3, 6, 12,
24, and 48 hours using MTT and LDH assays. Both Pb and Cd were cytotoxic to osteoblasts in
a concentration and duration dependent manner (Fig 1A–1D, Table 1, and S1 and S2 Tables).
Even at 0.1 μM, Pb and Cd were significantly cytotoxic to osteoblasts 48 hours post-treatment
(p = 0.035 and 0.023, respectively) (Fig 1A–1D and S1 and S2 Tables). Cd was more cytotoxic
than Pb with lower IC50s at all tested time points (Fig 1E, Table 1, and S1 and S2 Tables). That
these HMs induced a cytotoxic response was further confirmed via a BrdU cell proliferation
assay that demonstrated that neither agent stimulated osteoblast proliferation (results not
included).
3.2 Pb and Cd damage osteoblast bioenergetics
The investigation of cellular bioenergetics provided an additional independent evaluation of
osteoblast viability, and an insight to the molecular mechanism of cytotoxicity. Treatment of
osteoblasts with Pb or Cd for 24 hours at concentrations of 55 μM and 30 μM, respectively
(their IC50 values as determined using the MTT assay), significantly reduced intracellular ATP
levels to 58 and 54% of controls, respectively (p =<0.0001) (Fig 2A). Since the production of
ATP is governed by oxidative phosphorylation linked to the mitochondrial electron transport
system, a determination of the mitochondrial membrane potential, and activity assays for the
mitochondrial enzymes, complex I and complex III, were undertaken. A 24 hr exposure to Pb
Osteoblasts and lead and cadmium
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or Cd significantly reduced mitochondrial membrane potential (p< 0.0001) (Fig 2B), mito-
chondrial complex I activity (p = 0.0035) (Fig 2C), and mitochondrial complex III activity
(p = 0.0063) (Fig 2D). Cellular bioenergetics were also assessed using a polarographic assay
of oxygen consumption rates (OCRs). Pb or Cd significantly lowered osteoblast OCRs
(p< 0.0001) (Fig 2E), and, consistent with an inhibition of aerobic metabolism, both HMs
triggered a significant increase in the production of lactate (p = 0.0037) (Fig 2F).
Fig 1. Lead and cadmium cytotoxicity to human osteoblasts in vitro. Human osteoblasts were treated with lead or
cadmium over a concentration range of 0.1–1000 μM and for 3–48 hours and the level of cell metabolic activity and
viability determined by MTT and LDH assays (A-D). The concentrations of lead or cadmium that produced 50%
inhibition of metabolic activity or cell viability were determined (E). Data points are representative of 9 independent
experiments.
https://doi.org/10.1371/journal.pone.0225341.g001
Osteoblasts and lead and cadmium
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3.3 Pb and Cd damage osteoblasts via generation of redox stress
To assess redox stress, osteoblasts were incubated with Pb (55 μM) or Cd (30 μM) at their
MTT IC50 concentrations. Measurements of reactive oxygen species (ROS) were conducted in
situ using a dichlorofluorescin diacetate (DCFDA) assay. Pb or Cd significantly increased cel-
lular ROS production (p = 0.0023) by 39 and 54%, respectively (Fig 3A).
Table 1. IC50 values (μM) for lead and cadmium cytotoxicity to human osteoblasts in vitro.
Assay Duration of exposure (hr)
3 6 12 24 48
Pb (MTT) 604.2
(680.6–530.3)
411.2
(461.9–366.1)
137.8
(150.8–125.9)
54.9
(58.9–51.1)
27.8
(37.7–20.5)
Pb (LDH) 1139.2
(1283.4–1011.1)
678.6
(769.8–598.2)
276.5
(310.9–245.9)
78.8
(84.0–73.8)
37.4
(39.3–35.7)
Cd (MTT) 286.1
(323.5–253.3)
153.2
(167.8–139.9)
67.5
(75.4–60.3)
32.3
(36.7–28.5)
17.3
(18.5–16.1)
Cd (LDH) 588.7
(673.9–514.2)
309.1
(352.6–271.4)
157.7
(178.5–139.2)
63.0
(72.3–55.0)
29.9
(33.0–27.0)
https://doi.org/10.1371/journal.pone.0225341.t001
Fig 2. The effect of lead or cadmium on human osteoblast bioenergetics. Human osteoblasts were treated with lead
(Pb) (55 μM) or cadmium (Cd) (30 μM), and the production of cellular ATP (A), mitochondrial membrane potential
(B), mitochondrial complex I activity (C), mitochondrial complex III activity (D), oxygen consumption rate (OCR)
(E), and lactate levels (F) quantified. Significant differences from controls are marked with asterisks. Data are
representative of 6–9 independent experiments. For � = p-value< 0.05, �� = p-value< 0.01, ��� = p-value< 0.0001.
https://doi.org/10.1371/journal.pone.0225341.g002
Osteoblasts and lead and cadmium
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Fig 3. The effect of lead or cadmium on redox status of human osteoblasts. Human osteoblasts were treated with
lead (Pb) (55 μM) or cadmium (Cd) (30 μM) for 24 hours, and the production of ROS (A), catalase activity (B),
superoxide dismutase-1 (SOD-1) activity (C), intracellular reduced glutathione levels (D), production of thiobarbituric
acid reactive substances (TBARS) (E), and activation of Nrf2 (F) quantified. Human osteoblasts were treated with
reduced glutathione prior to treatment with lead or cadmium, and the level of cytotoxicity determined using an MTT
assay (G). Significant differences from controls are marked with asterisks. Data are representative of 5–9 independent
experiments. For � = p-value< 0.05, �� = p-value< 0.01, ��� = p-value< 0.0001.
https://doi.org/10.1371/journal.pone.0225341.g003
Osteoblasts and lead and cadmium
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We then investigated the activity of the cellular redox regulating enzymes, catalase and
superoxide dismutase (SOD), and the cellular levels of reduced glutathione. Pb or Cd signifi-
cantly decreased catalase activity to 45% and 36% of controls, respectively (p = 0.0006); SOD
activities to 65% and 59% of controls, respectively (p = 0.0066), and glutathione levels to 63%
and 56% of controls, respectively, (p = 0.0024) (Fig 3B–3D).
The redox stress triggered by Pb or Cd induced an increase of the levels of lipid peroxida-
tion products as thiobarbituric acid reactive substances (TBARS) by 78% and 69% of control
levels, respectively, (p = 0.002) (Fig 3E).
Induction of cellular redox stress by Pb or Cd was consistent with significant activation of
the nuclear (redox regulatory) transcription factor, Nrf2, by 2.32- and 2.98-fold, respectively
(p< 0.0001) (Fig 3F). To demonstrate that Pb or Cd induced redox stress contributed to
reduced cell viability, osteoblasts were pre-incubated with reduced glutathione (GSH) prior to
challenge with Pb or Cd. Pre-incubation with GSH significantly lowered the cytotoxic effects
of Pb (p = 0.0004) or Cd (p< 0.0001) (Fig 3G).
3.4 Pb and Cd toxicity affects human osteoblast secretory functions
The effect of HMs on the osteoblast production of procollagen type I peptide and osteocalcin
were quantified. The secretion of procollagen was significantly reduced in cells and also that
secreted into the media after a 24 hour incubation with Pb (55 μM) (p = 0.0126) or Cd (30μM)
(p = 0.0025) (Fig 4A).
The secretion of osteocalcin was quantified at 3, 6, 12, 24, and 48 hour time points after
treatment of osteoblasts with Pb (55 μM) or Cd (30μM). After 12, 24, or 48 hours the produc-
tion of osteocalcin was significantly reduced by Pb or Cd by 18 and 20% (p = 0.019), 26 and
30% (p = 0.002), and 13 and 24%, (p = 0.0004), respectively (Fig 4B).
The secretion and activity of ALP was quantified at 3, 6, 12, 24, and 48 hour time points
after treatment of osteoblasts with Pb (55 μM) or Cd (30μM). After 24 and 48 hours ALP was
significantly reduced by Pb or Cd by 26 and 30% (p = 0.026), and 18 and 20% (p = 0.0062),
respectively (Fig 4C).
Discussion
4.1 Lead and cadmium are cytotoxic to human osteoblasts
Our study examined the cytotoxic effects of two widely spread and encountered HMs, lead
and cadmium, and considered their direct effects on human osteoblasts in vitro. The four cell
types resident within bone: osteoblasts, osteoclasts, osteocytes, and bone lining cells exist in a
dynamic interaction and collectively form a basic multicellular unit (BMU) [18,20]. However,
for ease of study, and in order to delineate cell specific effects, analysis of a single homogeneous
population of cells is required. Hence, our approach was to utilize a human osteoblast cell line
rather than extraction of primary cells. This ensured the use of phenotypically similar cells,
avoided any species-specific responses, and has also been shown to provide results consistent
with primary cells [44].
Lead is toxic to a number of bodily systems, including bone. There are no safe levels of lead
exposure [23], with initial clinical symptomology that includes kidney dysfunction at a blood
lead level (BLL) of 5–10 μg/dL (0.24–0.48 μM). A spectrum of health impact is observed above
11 μg/dL, with cognitive impairment at 40–79 μg/dL, neuropathy at>80 μg/dL (�4 μM), and
encephalopathy at 100–120 μg/dL (�6 μM) [45]. Since levels of human intoxication from lead
exposure are correlated with BLL, we examined a broad concentration range that included
symptomatic BLL concentrations (0.1–1 μM), as well as gross intoxication (>10 μM).
Osteoblasts and lead and cadmium
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Noteworthy is the recent demonstration that bone lead levels significantly correlate with past
maximum and current BLLs [46].
The accumulation of cadmium is reflected by its 24 hour urinary excretion, and typically
reported as either nmol of cadmium excretion/day or as creatine-adjusted urinary cadmium
levels. For smelter workers occupationally exposed to lead and cadmium, blood cadmium lev-
els up to 0.145 μmol/L, and BLLs of 1–3.7 μmol/L have been reported [15]; comparable to our
0.1–1 μM exposure measurements. Furthermore, by using the same exposure concentration
range for cadmium as that employed for lead, we were able to make direct toxicity compari-
sons between the two HMs, and establish if similar mechanisms of toxicity existed at a given
exposure concentration.
Although BLL concentrations of>10 μM would be considered overdose levels, exposure of
cells in vitro at relatively high concentrations is used to model more chronic and cumulative
exposure within a limited period of study. Furthermore, HMs including lead and cadmium are
Fig 4. The effect of lead or cadmium (Cd) on human osteoblast secretions. Human osteoblasts were treated with
lead (Pb) (55 μM) or cadmium (Cd) (30 μM), and the level of procollagen type I peptide within the cells and released
into the culture media quantified (A). At 3, 6, 12, 24, and 48 hours post-treatment with lead or cadmium, the levels of
osteocalcin (B) and ALP (C) secreted into the culture media were quantified. Significant differences from controls are
marked with asterisks. Data are representative of 5 independent experiments. For � = p-value< 0.05, �� = p-
value< 0.01, ��� = p-value< 0.0001.
https://doi.org/10.1371/journal.pone.0225341.g004
Osteoblasts and lead and cadmium
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non-degradable, and have a slow rate of elimination (blood lead has a half-life of about 40 days
in humans, cadmium an elimination half-life of 20–30 years); they therefore can progressively
accumulate in tissues such as bone that sequesters HMs.
Both HMs were cytotoxic to osteoblasts in a concentrations and exposure durations depen-
dent manner, as assessed using a MTT assay (Fig 1, Table 1, S1 and S2 Tables). The tetrazolium
(MTT) assay is based upon the ability of NAD(P)H-dependent cellular oxidoreductase
enzymes to reduce MTT to formazan, but may not discriminate between cytostatic and cyto-
toxic agents. Hence, to confirm cytotoxicity of the HMs, production of extracellular LDH was
also quantified. The liberation of LDH relates to a loss of the cell membrane integrity experi-
enced at cell death. The LDH concentration curves for cell cytotoxicity mirrored those gener-
ated from MTT assays (refer to Fig 1), confirming that lead or cadmium induced cell death
with increasing concentration and duration of exposure. The threshold concentration for cell
death was 0.1 μM for both lead and cadmium, after a 48 hour and 24 hour exposure, respec-
tively. At 1 μM, cytotoxic effects were evident after 6 hours for lead and 3 hours for cadmium
(S1 and S2 Tables); concentrations comparable with BLLs, or cadmium blood levels experi-
enced by occupationally or environmentally exposed individuals [15].
Collectively, cadmium was more cytotoxic than lead, with lower IC50s at all tested time
points (refer to Table 1, S1 and S2 Tables). The cytotoxicity of lead or cadmium to either osteo-
blast-like cell lines, or primary osteoblasts is via induction of apoptosis and necrosis [47–49].
Even lower IC50s (higher sensitivity) have been reported using rat primary osteoblasts (IC50 of
2 μM for cadmium) [49], which may reflect species-specific effects as well as improved respon-
siveness of primary cells.
4.2 Lead and cadmium exposure impairs human osteoblast cellular
bioenergetics and generates redox stress
Our study demonstrated that lead or cadmium when applied to cells at 55 μM and 30 μM,
respectively, damaged osteoblast bioenergetics. A reduction of mitochondrial membrane
potential was evident, with disruption and inhibition of mitochondrial complex protein activi-
ties; components of the electron transport chain (ETC) crucial for cellular (aerobic) respiration
(Fig 2). A loss of electron transport and coupling to oxidative phosphorylation resulted in a
shift to anaerobic metabolism, with reduced oxygen consumption, increased lactate produc-
tion, and reduced ATP production (Fig 2).
The ability of toxic agents to induce damage to mitochondria and nullify ATP production
is a common mechanism of cellular damage, and contributes to cellular redox stress and
induction of apoptosis [50–56]. There is normally leakage of protons from the ETC into the
mitochondrial matrix. These protons can combine with oxygen molecules to form reactive
oxygen species (ROS); a process increased under pathological conditions [53,57]. ROS are able
to damage DNA, proteins, and lipids; the latter consistent with an increase in lipid peroxida-
tion (Fig 3E). The generation of ROS may be further self-propagating since ROS also damage
mitochondria and thereby promote membrane permeation, and potentially more ROS pro-
duction and accumulation of HMs [58].
ROS levels within osteoblasts increased in response to a 24 hour exposure to lead (55 μM)
or cadmium (30 μM), with cellular redox stress exacerbated by a reduction in the activities of
superoxide dismutase (SOD) and catalase, as well as diminished cellular glutathione levels (Fig
3). SOD catalyzes the dismutation of the superoxide radical to form either molecular oxygen
or hydrogen peroxide. Hydrogen peroxide can be decomposed to water and molecular oxygen
via the action of catalase. Glutathione is the major cellular thiol able to buffer and resist redox
stress. Hence, lead or cadmium induced redox stress will be compounded once SOD and
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catalase activity are compromised and glutathione depleted; as collectively they comprise
major elements of cellular redox defense. Consistent with our in vitro data, biomarkers of
redox stress have also been detected in blood after occupational exposure to lead or cadmium
[59,60]. Cells are able to resist the detrimental effects of xenobiotic and redox stress promoters
via activation of the transcription factor, nuclear factor E2-related factor 2 (Nrf2) [61,62]. We
detected significantly increased nuclear Nrf2 as a response to toxic levels of lead or cadmium
(Fig 3F). Upon appropriate cellular stimulus (including redox stress), Nrf2 translocates from
the cytoplasm to the nucleus to promote transcription of a vast array of cytoprotective genes,
including those for antioxidant and detoxificating enzymes [61,62]. At present we can only
speculate that the increased Nrf2 activity we have observed is to mitigate redox stress [63,64],
and a comprehensive determination of the transcriptional and translational changes induced
after Nrf2 activation are still required.
4.3 HMs decrease the secretory output from osteoblasts
The organic matrix of bone is primarily (�90%) comprised of collagenous proteins (predomi-
nantly type I collagen), as well as non-collagenous proteins such as osteocalcin and ALP
secreted by osteoblasts. This prompted us to consider the ability of osteoblasts to secrete type I
procollagen, osteocalcin, and ALP.
Treatment of osteoblasts with either lead or cadmium impaired the secretion of these pro-
teins (Fig 4). Collagen fibers, formed from secreted procollagen, contribute to the structural
strength of bone [21]. A toxic exposure to lead or cadmium that evokes a reduction of collagen
production may reduce bone strength, a process consistent with the increased fracture risk
associated with HM exposures [12,13].
Osteocalcin promotes bone mineralization and density, but also has an emerging role as
a bone-derived hormone that influences energy metabolism, and brain development and
cognition [65]. Notably, even at relatively low BLL, lead exposure in children results in cogni-
tive impairment and IQ deficits [4]. Given the growing appreciation of the importance of
osteocalcin in neuronal development, reduced osteocalcin production as a consequence of
elevated lead could impact on bone strength as well as contribute to the effects of lead on
neurodevelopment.
ALP functions to degrade phosphate-containing compounds, releasing phosphate ions
within the bone matrix vesicles to promote matrix crystallization. Reduced ALP levels and
associated activity would similarly be expected to limit bone strength and integrity.
4.4 Management of lead or cadmium exposure through treatment of redox
stress
The current treatment strategy for lead poisoning is via administration of chelating agents
[66,67]. This may be of acute benefit, with treatment of lead-exposed children with the chelat-
ing agent, succimer, able to reduce BLL after 1 week, but was without effect on BLL 1 year after
treatment, indicative of remobilization of lead from stores such as bone [68]. Thus, additional
acute, subacute, and chronic treatment options are needed to support current therapies. Since
the cytotoxicity to osteoblasts from lead or cadmium exposure was mediated in part by damage
to cellular bioenergetics and induction of redox stress, agents able to mitigate redox stress
may be useful for cellular preservation. This was tested by pre-incubation of osteoblasts with
reduced glutathione prior to exposure to HMs, and this improved cell viability (Fig 3F). Other
studies have also proposed the benefits of dietary supplementation as a means to resist acute or
subacute lead or cadmium induced redox stress in vivo [67,69], although whether this repre-
sents a useful chronic treatment has not yet been validated. Additionally, given the impact of
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these HMs on cellular bioenergetics, interventions that provide alternative respiratory sub-
strates, such as β-hydroxybutyrate could prove useful therapeutic interventions if able to
bypass or ameliorate HM-induced mitochondrial protein inhibition.
Conclusion
To conclude, the environmental and occupational pollutants lead and cadmium, damage cellu-
lar bioenergetics of human osteoblasts, and induce redox stress via ROS generation and limit-
ing the effectiveness of the cellular antioxidant defense systems. Osteoblast secretory functions
were significantly reduced in parallel with the HM-induced bioenergetics disruption and oxi-
dative damage (Fig 5). Since the induction of redox stress is one of the common mechanisms
by which these agents induce cellular damage and death, administering antioxidants may pro-
vide a useful adjunct to support the currently employed chelation therapy.
Supporting information
S1 Table. Cytotoxic effect of lead to human osteoblasts in vitro.
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Fig 5. Toxic effects of lead or cadmium to human osteoblasts. The heavy metals (HMs) lead and cadmium were
toxic to human osteoblasts in vitro. Both HMs damaged cellular bioenergetics; with reduced mitochondrial complex
activities, ATP production, and aerobic respiration. Both HMs induced cellular redox stress via increased production
of reactive oxygen species (ROS) with associated elevation of lipid peroxidation as thiobarbituric acid reactive
substances (TBARS). Both HMs limited cellular redox defence via a lowering of catalase (CAT) and superoxidase
dismutase-1 (SOD-1) activities, and reduced glutathione levels. Damaged mitochondria can liberate more ROS that in
turn will further damage mitochondria ($). The transcription factor Nrf2 was activated in response to HMs, and
presumably acts to mitigate some of the mitochondrial and redox damage via upregulation of antioxidant genes. HM
damaged osteoblasts displayed functional deficits with reduced secretion of procollagen type I, osteocalcin, and
alkaline phosphatase (ALP).
https://doi.org/10.1371/journal.pone.0225341.g005
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